Public Scientific Service (hereinafter referred to as the “VPOIS”) concerned with medicinal products in accordance with § 33, Paragraph 3g), Section 1 of Act No. 378/2007 Coll., on Pharmaceuticals and on Amendments to Some Related Acts (Act on Pharmaceuticals)
|Název přípravku||SmPC||PIL||dodáván do ČR|
|ADASUVE||SmPC Adasuve||PIL Adasuve||NE|
|ADEPEND 50 MG POTAHOVANÉ TABLETY||SmPC Adepend||PIL Adepend||NE|
|AMBRISENTAN AOP||SmPC Ambrisentan AOP||PIL Ambrisentan AOP||NE|
|ANAGRELID AOP||SmPC Anagrelid AOP||PIL Anagrelid AOP||NE|
|BESREMI||SmPC Besremi||PIL Besremi||ANO|
|EMBESIN||SmPC Embesin||PIL Embesin||ANO|
|ESMOCARD||SmPC Esmocard||PIL Esmocard||ANO|
|ESMOCARD LYO||SmPC Esmocard LYO||PIL Esmocard LYO||ANO|
|NALBUPHIN ORPHA||SmPC Nalbuphin Orpha||PIL Nalbuphin Orpha||ANO|
|NALTREXONE AOP 50 MG||SmPC Naltrexone AOP||PIL Naltrexone AOP||NE|
|OCALIVA||SmPC Ocaliva||PIL Ocaliva||ANO|
|RAPIBLOC||SmPC Rapibloc||PIL Rapibloc||ANO|
|TADALAFIL AOP||SmPC Tadalafil AOP||PIL Tadalafil AOP||ANO|
|TETMODIS||SmPC Tetmodis||PIL Tetmodis||ANO|
|THROMBOREDUCTIN||SmPC Thromboreductin||PIL Thromboreductin||ANO|
|TREPULMIX||SmPC Trepulmix||PIL Trepulmix||NE|
|TRESUVI||SmPC Tresuvi||PIL Tresuvi||ANO|
|WAKIX||SmPC Wakix||PIL Wakix||ANO|
AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.
Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.
Esmocard® Lyo Esmolol Amomed
"Esmolol hydrochloride is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician’s judgement the rapid heart rate requires specific intervention."
"for short-term relief of moderate to severe pain. E.g. post-surgery, in labour pain and gynaecology, in myocardial infarction. Antagonizing an opioid induced respiratory depression, e.g. following fentanyl-combined narcosis. use in a combined narcosis ."
Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.